(Reuters) – Upstream Bio, which is developing treatments for some respiratory disorders, said on Thursday it had raised $255 million in its initial public offering in the United States.
(Reporting by Gursimran Kaur and Arasu Kannagi Basil in Bengaluru; Editing by Alan Barona)
Comments